8-K: Syndax Pharmaceuticals Appoints Dr. Aleksandra Rizo to Board, Replacing Dr. Briggs Morrison

Syndax Pharmaceuticals has appointed Dr. Aleksandra Rizo to its Board of Directors, effective immediately, replacing Dr. Briggs Morrison who has stepped down.

Summary

• Syndax Pharmaceuticals has appointed Dr. Aleksandra Rizo to its Board of Directors, effective immediately.
• Dr. Rizo will also serve on the Science and Technology Committee.
• She replaces Dr. Briggs Morrison, who resigned from the board.
• Dr. Rizo will receive an annual cash compensation of $45,644 for her board service and $8,558 for her committee service, prorated for 2024 and paid quarterly.
• She was also granted an initial option to purchase 35,000 shares of the company's common stock, vesting monthly over three years.
• The company held its annual meeting of stockholders on May 15, 2024, where all proposals, including the election of directors, were passed.
• The proposals included the election of directors, an advisory vote on executive compensation, and the ratification of the selection of an independent registered public accounting firm.

Sentiment

Score: 7

Explanation: The document reflects a positive change with the appointment of a highly qualified board member, but also includes the departure of a long-term member. The overall tone is optimistic about the company's future, but there are inherent risks in the biopharmaceutical industry.

Positives

• Dr. Rizo brings extensive clinical development experience and a track record of successfully leading the development of several hematology drugs.
• Her expertise is expected to be valuable as Syndax transitions to a commercial-stage organization.
• The company is progressing towards the potential launch of two novel treatments in 2024.
• The annual meeting of stockholders passed all proposals, indicating shareholder support.

Negatives

• The resignation of Dr. Briggs Morrison, although not due to any disagreement, represents a loss of a long-term board member.

Risks

• The company's forward-looking statements are subject to risks and uncertainties, including unexpected safety or efficacy data, lower than expected clinical trial enrollment, changes in competition, and regulatory changes.
• There is a risk of failure of collaborators to support or advance collaborations or product candidates.
• Unexpected litigation or other disputes could also impact the company's performance.

Future Outlook

Syndax is transitioning to a fully integrated commercial stage organization with the potential to launch two novel treatments in 2024. The company is focused on maximizing the opportunity for the launch and future development of its firstand best-in-class medicines.

Management Comments

• Dennis Podlesak, Chairman of Syndax's Board of Directors, stated that they are delighted to welcome Aleksandra to Syndax and look forward to the valuable perspectives she will bring.
• Michael A. Metzger, Chief Executive Officer, noted that Dr. Rizo's clinical development experience and guidance will be invaluable to Syndax as they maximize the opportunity for the launch and future development of their two firstand best-in-class medicines.
• Dr. Rizo stated that she is excited to join Syndax's Board at this transformative time for the company and believes that both revumenib and axatilimab have the clinical profiles to become the new standard of care within their disease areas.

Industry Context

The appointment of Dr. Rizo, a seasoned hematology drug developer, aligns with Syndax's focus on advancing its pipeline of cancer therapies, particularly in hematology. This move is consistent with the industry trend of bringing in experienced leaders to guide companies through commercialization phases.

Comparison to Industry Standards

• The appointment of a Chief Medical Officer or similar role to the board is a common practice in the biopharmaceutical industry, especially for companies transitioning to commercialization.
• Dr. Rizo's experience at companies like Celgene and Janssen, which have successfully launched hematology drugs, is comparable to the expertise sought by other companies in the sector.
• The compensation package for board members, including cash and stock options, is within the typical range for publicly traded biopharmaceutical companies of similar size and stage.

Management Changes

Stakeholder Impact

• Shareholders may view the appointment of Dr. Rizo positively, given her experience and the company's focus on commercialization.
• Employees may be encouraged by the company's progress and the addition of a seasoned leader.
• Customers and patients may benefit from the potential launch of new treatments.

Next Steps

• Dr. Rizo will begin her service on the Board and the Science and Technology Committee.
• The company will continue to work towards the potential launch of its two novel treatments in 2024.
• The company will continue to execute its clinical and corporate development plans.

Key Dates

Keywords

Board of Directors, Aleksandra Rizo, Briggs Morrison, Syndax Pharmaceuticals, Science and Technology Committee, Director Appointment, Annual Meeting, Executive Compensation, Hematology, Oncology